Genevi is a women’s health company focused on reimagining urinary incontinence treatment by addressing the urethra, which it identifies as the condition’s underlying source, rather than managing leakage alone. An Origyn Solutions portfolio company, Genevi highlights the unmet need among women: many experience urinary incontinence, but relatively few seek medical care, often managing symptoms privately for years.

The company’s approach is based on research linking incontinence to reduced urethral closure pressure and age-related loss of urethral muscle and nerve tissue. Genevi contrasts this focus with common treatments such as pelvic-floor exercises, physical therapy, medication, injections, and surgery, which it says often target symptoms or surrounding support structures rather than the urethral muscle itself.

Genevi is developing the Genevi Urethral Health System and invites clinicians, partners, and interested women to contact the company and follow its progress. The system is not FDA-cleared or approved for commercial distribution in the United States and is not currently available for sale or clinical use there.